MLL-rearranged acute lymphoblastic leukemia (ALL) occurring in infants is a rare but very aggressive leukemia, typically associated with a dismal prognosis. Despite the development of specific therapeutic protocols, infant patients with MLL-rearranged ALL still suffer from a low cure rate. At present, novel therapeutic approaches are urgently needed. Recently, the use of small molecule inhibitors targeting the epigenetic regulators of the MLL complex emerged as a promising strategy for the development of a targeted therapy. Herein, we have investigated the effects of bromodomain and extra-terminal (BET) function abrogation in a preclinical mouse model of MLL-AF4 + infant ALL using the BET inhibitor I-BET151. We reported that I-BET151 is able to arrest the growth of MLL-AF4 + leukemic cells in vitro, by blocking cell division and rapidly inducing apoptosis. Treatment with I-BET151 in vivo impairs the leukemic engraftment of patient-derived primary samples and lower the disease burden in mice. I-BET151 affects the transcriptional profile of MLL-rearranged ALL through the deregulation of BRD4, HOXA7/HOXA9, and RUNX1 gene networks. Moreover, I-BET151 treatment sensitizes glucocorticoid-resistant MLL-rearranged cells to prednisolone in vitro and is more efficient when used in combination with HDAC inhibitors, both in vitro and in vivo. Given the aggressiveness of the disease, the failure of the current therapies and the lack of an ultimate cure, this study paves the way for the use of BET inhibitors to treat MLL-rearranged infant ALL for future clinical applications.

Bardini, M., Trentin, L., Rizzo, F., Vieri, M., Savino, A., Castro, P., et al. (2018). Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL. MOLECULAR CANCER THERAPEUTICS, 17(8), 1705-1716 [10.1158/1535-7163.MCT-17-1123].

Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL

Bardini, Michela
;
Savino, Angela M.;Fazio, Grazia;Biondi, Andrea;Cazzaniga, Gianni
Ultimo
2018

Abstract

MLL-rearranged acute lymphoblastic leukemia (ALL) occurring in infants is a rare but very aggressive leukemia, typically associated with a dismal prognosis. Despite the development of specific therapeutic protocols, infant patients with MLL-rearranged ALL still suffer from a low cure rate. At present, novel therapeutic approaches are urgently needed. Recently, the use of small molecule inhibitors targeting the epigenetic regulators of the MLL complex emerged as a promising strategy for the development of a targeted therapy. Herein, we have investigated the effects of bromodomain and extra-terminal (BET) function abrogation in a preclinical mouse model of MLL-AF4 + infant ALL using the BET inhibitor I-BET151. We reported that I-BET151 is able to arrest the growth of MLL-AF4 + leukemic cells in vitro, by blocking cell division and rapidly inducing apoptosis. Treatment with I-BET151 in vivo impairs the leukemic engraftment of patient-derived primary samples and lower the disease burden in mice. I-BET151 affects the transcriptional profile of MLL-rearranged ALL through the deregulation of BRD4, HOXA7/HOXA9, and RUNX1 gene networks. Moreover, I-BET151 treatment sensitizes glucocorticoid-resistant MLL-rearranged cells to prednisolone in vitro and is more efficient when used in combination with HDAC inhibitors, both in vitro and in vivo. Given the aggressiveness of the disease, the failure of the current therapies and the lack of an ultimate cure, this study paves the way for the use of BET inhibitors to treat MLL-rearranged infant ALL for future clinical applications.
Articolo in rivista - Articolo scientifico
Oncology; Cancer Research
English
2018
17
8
1705
1716
reserved
Bardini, M., Trentin, L., Rizzo, F., Vieri, M., Savino, A., Castro, P., et al. (2018). Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL. MOLECULAR CANCER THERAPEUTICS, 17(8), 1705-1716 [10.1158/1535-7163.MCT-17-1123].
File in questo prodotto:
File Dimensione Formato  
bardini_iBET.pdf

Solo gestori archivio

Tipologia di allegato: Author’s Accepted Manuscript, AAM (Post-print)
Dimensione 1.3 MB
Formato Adobe PDF
1.3 MB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/226340
Citazioni
  • Scopus 17
  • ???jsp.display-item.citation.isi??? 13
Social impact